Dr Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Medical Director of the Institute of Personalized Cancer Therapy. She has extensive experience in novel therapeutics, with a focus on genomically-informed therapeutics and antibody-drug conjugates, as well as high throughput -omic technologies and correlative studies. She leads one of the premiere Phase I programs in the world, as well as several large-scale initiatives in precision oncology such as ComboMATCH. She has established a Precision Oncology Decision Support Team at MD Anderson that provides point of care input for actionability, builds a framework for rapid assessment of actionability of molecular alterations, launched a public website “www.personalizedcancer therapy.org” providing access to expert curation of information on therapeutic relevance of specific genes/variants created, created a knowledgebase and clinical trial alert systems that facilitate accrual to genotype-selected trials across the institution, and established efforts to monitor therapy after genomic testing to identify obstacles to trial enrollment. She also leads a basic and translational research program centered around cell signaling, biomarker discovery, and molecular therapeutics, with specific focus on antibody-drug conjugates, precision oncology, and patient-derived models.